Menopause News

The cause of midlife migraines in women is likely multifactorial, though research suggests that fluctuating hormone levels may play a role, according to a speaker at the North American Menopause Society annual meeting.

Menopausal hormone therapy is safe and effective for many women experiencing bothersome symptoms like hot flashes, but treatment should be individualized for people with certain risk factors, according to a speaker.

In this video, NAMS medical director Stephanie Faubion, MD, discusses highlights from her presentation at the organization’s annual meeting on nonhormone therapies currently being investigated for the management of vasomotor symptoms.

Women with sedentary lifestyles face a greater risk for experiencing hot flashes at night, according to a study presented at the North American Menopause Society Annual Meeting.

An investigational nonhormonal therapy for moderate to severe hot flashes significantly reduced symptom frequency at 12 weeks compared with placebo, with improvements observed as early as 1 week after treatment, data from SKYLIGHT 2 show.

As the cardiovascular profiles of women deteriorate after menopause, they may see a greater risk for dementia, according to a study presented during the North American Menopause Society Annual Meeting.

Menopause-related sleep fragmentation has downstream effects on mood, daytime wellbeing and metabolism, even when women meet recommended guidelines for normal sleep duration, according to a speaker.

Premature menopause was associated with an increased risk for atherosclerotic CVD, according to new findings published in JAMA Cardiology.

Estrogen dosage, the type of formulation and the number of years since menopause may alter a woman’s risk for hypertension, according to data from the Women’s Health Initiative Observational Study published in Menopause.

NAMS has released a position statement reflecting the latest thinking and findings regarding the management of osteoporosis in postmenopausal women.